Haystack MRD Test Shows High Accuracy in Detecting Colorectal Cancer Recurrence
Event summary
- Haystack MRD® test demonstrated 100% specificity and 100% sensitivity at 3-year follow-up, and 83.3% sensitivity at 5-year follow-up in detecting colorectal cancer recurrence.
- The test outperformed carcinoembryonic antigen (CEA), detecting recurrence with 88.9% sensitivity versus 11.1% for CEA.
- Haystack MRD achieved a 95% limit of detection (LoD95) of 0.063 mean ctDNA molecules per milliliter of plasma.
- The study validated the test’s analytical performance across 23 solid tumor types.
- Haystack MRD is now authorized for patient access in all 50 U.S. states.
The big picture
The robust clinical performance of Haystack MRD underscores the growing role of liquid biopsy technologies in personalized cancer care. Quest Diagnostics is positioning itself at the forefront of this shift, leveraging its extensive diagnostic network to bring advanced molecular testing to a broader patient population. The validation across multiple solid tumor types suggests significant potential for market expansion, though regulatory and clinical adoption hurdles remain.
What we're watching
- Clinical Adoption
- How quickly clinicians will integrate Haystack MRD into standard care protocols for colorectal cancer and other solid tumors.
- Regulatory Approval
- Whether the FDA Breakthrough Device Designation will accelerate broader regulatory approvals for Haystack MRD in other cancer types.
- Market Expansion
- The pace at which Quest Diagnostics can expand the commercial use of Haystack MRD beyond colorectal cancer into other solid tumor indications.
Related topics
